Did OPL's TrialKey AI-based predictive clinical trial platform...

Did OPL's TrialKey AI-based predictive clinical trial platform forecast the failure of CSL's Phase 3 AEGIS-11 trial of the CSL112 heart drug?

There's a >90% chance that it did.

Which means that if investors applied the TrialKey tech to the CSL112 trial(s) they could have avoided being damaged in yesterday's $8b CSL market capitalization fall.

Indeed, they could have profited from CSL derivatives such as put options.

Where does the 90% TrialKey accuracy claim come from?

On January 31, 2024, OPL issued a Business Update that said this: "Opyl continued to make key technology improvements to functionality, user experience and accuracy of the TrialKey platform during the quarter.

These improvements resulted in a significant enhancement in TrialKey’s predictive performance to over 90%..."

Meanwhile, over at Linkedin, Opyl is making other claims.

The group says that after it applied AI analysis to more than 800 COVID-19-related clinical trials it correctly predicted - even before Phase 3 trials had concluded - that Moderna and Pfizer would emerge with the most successful COVID vaccine solutions.

How can Opyl convert TrialKey's AI forecasting features to income?

1. By targeting biotech fund managers and other investors with a data subscription product priced at $2,000-$3,000 a month.

2. Selling bespoke clinical trial predictive intelligence reports for ~$50,000 each.

While Opyl has flagged these initiatives in recent ASX reports, the market seems oblivious.